Glucagon-like peptide-1 (GLP-1) receptor agonists used to treat type 2 diabetes and obesity may also help to lower the risk of addiction to a range of substances including… read more.
Eli Lilly and Company announced the FDA approved a label expansion for Zepbound (tirzepatide) to include the four-dose single-patient use KwikPen that delivers a full month of treatment… read more.
An international research group has examined how many people are affected by preclinical and clinical obesity and what health risks are associated with this. The team led by… read more.
The EMA’s CHMP adopted a positive opinion, recommending the granting of a conditional marketing authorisation for Kayshild (semaglutide), intended for the treatment of adults with non-cirrhotic metabolic dysfunction-associated… read more.
A new study from Adelaide University is turning a spotlight on those tablet versions, finding that the absorption-enhancing ingredient salcaprozate sodium (SNAC) may have measurable adverse biological effects for the gut and… read more.
Researchers from a large international study report that obesity significantly increases the risk of hospitalization and death from many infectious diseases, including flu, COVID-19, pneumonia, gastroenteritis, urinary tract… read more.
Novo Nordisk announced that the FDA has approved the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and… read more.
An estimated 1.6 million adults in England, Wales and Scotland used drugs such as Wegovy and Mounjaro to help lose weight between early 2024 and early 2025, according… read more.
Researchers report that ending the use of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss is associated with weight regain and a reversal of heart health markers. The… read more.
When Americans begin taking appetite-suppressing drugs like Ozempic and Wegovy, the changes extend well beyond the bathroom scale. According to new Cornell University research, the medications are associated… read more.
Novo Nordisk announced the submission of a sNDA to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg, to be used… read more.
The EU drug watchdog, the European Medicines Agency (EMA), has launched a partnership with social media influencers to promote the safe use of GLP-1 receptor agonists. The #HealthNotHype… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
